JPRN-UMIN000053351招募中Unknown
EC and Pembrolizumb combination therapy with Pegfilgrastim as primary prevention - ECOLOGY
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Those who not gave written informed consent
研究者
相似试验
招募中
不适用
Effect of combination therapy of Pegylated interferon- Alpha 2a, Sofosbuvir and Ribavirin for 12 weeks versus combination of Sofosbuvir and Ribavirin for 24 weeks on viral loads in HCV Genotype 3 chronic hepatitis & compensated cirrhosis patientsHCV genotype 3 related chronic hepatitis & compensated cirrhosisSLCTR/2017/007Department of Hepatology Bangabandhu Sheikh Mujib Medical University
已完成
不适用
PEG-IFN-alfa2b/Ribavirin combination therapy for chronic hepatitis C patients with low platelet count: efficacy and safetychronic hepatitis CJPRN-UMIN000002377Kanazawa university100
进行中（未招募）
不适用
Epirubicine plus Cyclophosphamid followed by Docetaxel +/- Sunitinib before surgery for the treatment of patients with HER2neu-negative operable breast cancerHER2neu-negative operable breast cancerEUCTR2009-009874-28-ATABCSG - Austrian Breast & Colorectal Cancer Study Group
已完成
不适用
The combination therapy of PEG-IFN alpha 2b, Ribavirin and Telaprevir for the patients with chronic hepatitis C:the study for treatment duration by response guided therapy and prediction of efficacy by gene analysis in Japan.chronic hepatitis CJPRN-UMIN000018971agoya university500
已完成
1 期
oral CEF(Cyclophosphamide, Epirubicin, UFT) adjuvant chemotherapy for breast cancer with intra-patient dose escalatioBreast cancerJPRN-C000000429Outpatient Oncology Unit Kyoto University Hospital26